First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: Paysign: the setup is constructive — New plasma center contract wins and cardholder additions - each major plasma operator represents thousands of potential…
growth - The 23.5% revenue growth, 7.5% FCF yield, and niche market positioning attract small-cap growth investors seeking exposure…
Rising rates create modest headwinds through two channels: (1) higher discount rates compress valuation multiples for unprofitable growth…
Watch on earnings: Monthly active cardholders by vertical (plasma, clinical trials, pharma) - primary growth indicator, Transaction volume per card (monthly spend velocity) - measures platform engagement and interchange revenue potential, Plasma center industry consolidation activity - M&A among donation operators affects contract stability and pricing leverage.
One Sentence Summary:
The bull case is simple: analysts see revenue climbing from $109M to $125M as new plasma center contract wins and cardholder additions - each major plasma operator represents thousands of potential.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.